Register entry
MELINTA SUBSIDIARY CORP
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 16
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
16| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7635773 | BAXDELAdelafloxacin meglumine | product | Mar 2029 |
| 8410077 | BAXDELAdelafloxacin meglumine | product | Mar 2029 |
| 9200088 | BAXDELAdelafloxacin meglumine | product | Mar 2029 |
| 9750822 | BAXDELAdelafloxacin meglumine | product | Mar 2029 |
| 8871938 | BAXDELAdelafloxacin meglumine | substance | Sept 2029 |
| RE46617 | BAXDELAdelafloxacin meglumine | substance | Dec 2029 |
| 7728143 | BAXDELAdelafloxacin meglumine | substance | Jun 2031 |
| 12138257 | BAXDELAdelafloxacin meglumine | product | May 2032 |
| 9493582 | BAXDELAdelafloxacin meglumine | product | Feb 2033 |
| 12558349 | BAXDELAdelafloxacin meglumine | use | Mar 2034 |
| 12036219 | BAXDELAdelafloxacin meglumine | use | Jun 2034 |
| Product | Exclusivity | Until |
|---|---|---|
| BAXDELADELAFLOXACIN MEGLUMINE | GAIN Qualified infectious disease product (GAIN) | Jun 2027 |
Enquiry
Common questions
- Is MELINTA SUBSIDIARY CORP FDA approved?
- MELINTA SUBSIDIARY CORP holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.